title: Biologic modulators in allergic and autoinflammatory diseases.
abstract: OBJECTIVE
  The advent of molecular techniques has resulted in the ability to tailor medications to specific protein targets. This review will emphasize several biological therapies, specifically directed toward cytokine receptors and inhibitors, and their role in the treatment of atopic and autoinflammatory diseases.
  
  
  RESULTS
  Translational research and the identification of the molecular pathophysiology of diseases have led to more targeted treatment approaches. The biologic modulators encompassing monoclonal antibodies as cytokine inhibitors, receptor blocking antibodies, and new fusion receptors are now being applied to diseases beyond their original application.
  
  
  CONCLUSIONS
  The expanded use of biological therapies has experienced success in the treatment of numerous disorders, especially in subsets of patients with disease that has been refractory to conventional therapies.
authors.affiliation: Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, San Diego, California 92093, USA. lbroderick@ucsd.edu
authors.forename: Lori
authors.initials: L
authors.lastname: Broderick
authors.forename: Louanne M
authors.initials: LM
authors.lastname: Tourangeau
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: Stephen I
authors.initials: SI
authors.lastname: Wasserman
mesh_terms: D000707:Anaphylaxis / Q000188:drug therapy; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000235:genetics; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D004311:Double-Blind Method; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000235:genetics; D007073:Immunoglobulin E / Q000276:immunology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics; D008223:Lymphoma / Q000209:etiology; D058990:Molecular Targeted Therapy; D016032:Randomized Controlled Trials as Topic; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012130:Respiratory Hypersensitivity / Q000188:drug therapy; D057170:Translational Research, Biomedical
chemical_list: D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D016207:Cytokines; D007166:Immunosuppressive Agents; D018121:Receptors, Cytokine; D011993:Recombinant Fusion Proteins; D007073:Immunoglobulin E